Journal of Medical Imaging and Radiation Oncology最新文献

{"title":"Ethnic Differences in Outcomes of Endovascular Thrombectomy in New Zealand.","authors":"Jaron Huang, Alicia Tyson, Muthu Muthappan, Annemarei Ranta","doi":"10.1111/1754-9485.70187","DOIUrl":"https://doi.org/10.1111/1754-9485.70187","url":null,"abstract":"<p><strong>Introduction: </strong>Stroke is a leading cause of morbidity and mortality in New Zealand, with ethnic disparities known to exist. Endovascular thrombectomy (EVT) has proven efficacy in reducing or preventing disability for stroke patients, but little is known about ethnic differences in functional outcomes following EVT in New Zealand.</p><p><strong>Methods: </strong>A retrospective nationwide registry-based study was conducted, including all patients who underwent EVT between 1st January 2011 through to 31st December 2023 in New Zealand. Demographic, clinical and procedural data were obtained from the National Stroke Register. Primary outcomes were mortality at 7 days and dichotomised modified Rankin Scale (mRS) at 90 days. Subgroup analysis compared patients presenting directly to EVT-capable centres with those requiring transfer.</p><p><strong>Results: </strong>2852 EVT patients were included (68.7% European, 14.6% Māori, 7.4% Pacific, 8.4% Asian and 1.0% Other). Non-Europeans presented at younger ages and with greater vascular risk factors. Functional outcomes and 7-day mortality rates did not differ significantly by ethnicity. Odds of symptomatic intracranial haemorrhage (sICH) were greater in Māori (aOR 3.01, 1.42-6.38, p = 0.004), Pacific peoples (3.40, 1.22-9.53, p = 0.02) and Asian (aOR 3.57, 1.57-8.15, p = 0.002) patients compared to Europeans. Nearly half of patients (46.5%) initially presented to non-EVT capable centres; although EVT was delayed, functional and mortality outcomes remained similar.</p><p><strong>Conclusion: </strong>This nationwide study found no significant ethnic disparities in functional outcomes or 7-day mortality following EVT, though sICH was more likely in non-Europeans. Despite treatment delays, patients initially presenting to non-EVT capable centres achieved comparable functional outcomes to those presenting directly to EVT centres.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148969221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pseudoangiomatous Stromal Hyperplasia of the Breast: Clinical, Radiologic and Histopathologic Spectrum in a Retrospective Single-Centre Series.","authors":"Sedef Mevlüde Karaböcek, Seda Aladag Kurt, Ceyda Sönmez Wetherilt, Berrin Papila, Tulin Ozturk, Mehmet Halit Yılmaz, Yasemin Kayadibi","doi":"10.1111/1754-9485.70186","DOIUrl":"https://doi.org/10.1111/1754-9485.70186","url":null,"abstract":"<p><strong>Purpose: </strong>Pseudoangiomatous stromal hyperplasia (PASH) is a benign mesenchymal breast lesion with a broad spectrum of clinical and radiologic presentations. We aimed to evaluate the demographic, radiologic and histopathologic features of PASH-containing breast lesions.</p><p><strong>Methods: </strong>This retrospective single-centre study included patients with histopathologically confirmed PASH identified between January 2019 and January 2026. Clinical records, mammography, ultrasonography, MRI findings and pathology reports were reviewed. Imaging findings were analysed descriptively together with demographic and histopathologic characteristics.</p><p><strong>Results: </strong>Thirty-one female patients with a mean age of 34.1 ± 11.7 years (range, 11-51 years) were included. Most patients were premenopausal (29/31, 94%). PASH was most commonly identified as an incidental or associated stromal finding, particularly in fibroadenoma-spectrum lesions (18/31, 58%). On ultrasonography, the predominant appearance was an oval, parallel-oriented, hypoechoic lesion with circumscribed margins, although suspicious findings such as indistinct margins and non-parallel orientation were also observed. Mammographic findings ranged from negative examinations to mass-like densities and calcifications. MRI appearances were heterogeneous and included both mass and non-mass enhancement patterns. Two young patients demonstrated rapidly enlarging dominant diffuse/nodular PASH lesions with diffusion restriction on MRI, raising preoperative suspicion for angiosarcoma and ultimately requiring surgical management.</p><p><strong>Conclusion: </strong>Breast PASH demonstrates substantial biologic and radiologic heterogeneity, ranging from incidental stromal findings within benign proliferative lesions to rapidly enlarging diffuse/nodular masses with aggressive imaging features mimicking angiosarcoma. Because imaging findings may reflect both the PASH component and associated breast pathology, radiologic-pathologic correlation is essential for accurate diagnosis and appropriate management.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adoption of Hypofractionated Radiation Therapy and Quality of Life Outcomes for Localised Prostate Cancer in an Australian Population-Based Cohort.","authors":"Therese Min Jung Kang, Diane Laura Lim, Sunwoo Kim, David Chang, Sarat Chander, Michael Ng, Jonathan Tomaszewski, Jonathan Bensley, Michelle Steeper, Krupa Krishnaprasad, Maggie Johnson, Nikolajs Zeps, Jeremy Millar, Wee Loon Ong","doi":"10.1111/1754-9485.70183","DOIUrl":"https://doi.org/10.1111/1754-9485.70183","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to evaluate the adoption of hypofractionated radiotherapy (HFRT) for localised prostate cancer (PCa) and the quality of life (QOL) outcomes at a population-based level in Victoria.</p><p><strong>Methods: </strong>This is a population-based cohort of individuals with PCa registered in the Victorian Prostate Cancer Outcomes Registry (PCOR-Vic) who had radiotherapy between 2016 and 2023. The primary outcomes were the proportion of individuals who had HFRT, and QOL 12 months post-treatment assessed using the EPIC26 questionnaire. Multivariable logistic regressions were used to evaluate factors associated with HFRT use, and linear regressions were used to estimate differences in EPIC26 domain scores between HFRT and conventional fractionated radiotherapy (CFRT).</p><p><strong>Results: </strong>There were 3647 individuals included in the study-213 (6%) low-risk PCa, 1799 (49%) intermediate-risk PCa, and 1635 (45%) high-risk PCa. There were 1729 (47%) individuals who had HFRT. The use of HFRT increased from 2% for the whole cohort in 2016 to 87% for low-intermediate risk PCa and 52% for high-risk PCa in 2023. In multivariable analyses, increased age, low-intermediate risk PCa, and more recent years of treatment were independently associated with treatment with HFRT. Among individuals who completed the 12-month post-treatment EPIC26 questionnaire, no statistically or clinically significant differences in urinary and bowel QOL outcomes were observed between HFRT and CFRT.</p><p><strong>Conclusion: </strong>There was a significant increase in the adoption of HFRT in this contemporaneous population-based cohort of individuals who had radiotherapy for localised PCa in Victoria. At a population-based level, there was no evidence of differences in QOL outcomes at 12 months after HFRT and CFRT.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging Temporal and Spatial Scales: Contemporary Advances in EEG-fMRI Integration With a Focus on Epilepsy.","authors":"Farkhanda Haider Taj, Taiba","doi":"10.1111/1754-9485.70182","DOIUrl":"https://doi.org/10.1111/1754-9485.70182","url":null,"abstract":"<p><strong>Introduction: </strong>Epilepsy is a chronic neurological disorder characterized by recurrent seizures resulting from abnormal neuronal activity. Accurate localization of epileptogenic regions is critical for effective diagnosis and management, particularly in drug-resistant cases. Electroencephalography (EEG) and functional magnetic resonance imaging (fMRI) are complementary neuroimaging techniques that provide high temporal and spatial resolution, respectively.</p><p><strong>Methods: </strong>This review synthesizes recent literature on the integration of EEG and fMRI, focusing on methodological developments, data acquisition strategies, and analytical approaches relevant to epilepsy research.</p><p><strong>Result: </strong>EEG-fMRI integration enhances the ability to capture both the temporal dynamics and spatial localization of epileptic activity, offering insights that may not be achievable using either modality alone. Recent advances demonstrate improved characterization of epileptogenic networks and potential clinical utility in presurgical evaluation.</p><p><strong>Conclusion: </strong>EEG-fMRI integration represents a promising approach for advancing the understanding and management of epilepsy. However, technical, analytical, and translational challenges remain, and further research is required to facilitate broader clinical adoption.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148956134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MRI-Guided SBRT Boost for Patients With Locally Advanced Cervical Cancer Who Are Unsuitable for Standard of Care Image-Guided Brachytherapy.","authors":"L Edwards, H Tan, K Rahim, E Leong, M Carrillo-Serrano, T Liang, H L Byrne, J De Leon, S Sia, R Chee","doi":"10.1111/1754-9485.70185","DOIUrl":"https://doi.org/10.1111/1754-9485.70185","url":null,"abstract":"<p><strong>Introduction: </strong>In recent years, cervical cancer incidence has been on the decline in Australia, likely due to the HPV vaccination and an improved screening programme. However, an estimated 900 new cases will be diagnosed in 2025. The standard of care for locally advanced cervical cancer (LACC) is chemoradiotherapy, comprising external beam radiation therapy with concurrent cisplatin followed by image guided brachytherapy (IGBT), which is essential for optimal local control. Some patients will be ineligible for IGBT due to comorbidities, anaesthetic risk or technical challenges, with alternative EBRT boost techniques demonstrating higher toxicity and poorer patient outcomes. MR-guided stereotactic body radiotherapy (MRg-SBRT) offers improved soft tissue visualisation and daily adaptive planning, enabling accurate target coverage and reduced dose to organs at risk. MRg-SBRT is an investigational non-invasive boost option with emerging evidence supporting feasibility METHODS: We describe our early experience treating four patients with cervical cancer who were ineligible for IGBT following pelvic EBRT ± chemotherapy. All patients completed treatment with adaptive MRg-SBRT.</p><p><strong>Results: </strong>Median high-risk clinical target volume (HR-CTV) D98% was 78.7 Gy EQD2₁₀, demonstrating adequate target coverage. Early imaging showed one complete response, one local progression and one combined local and metastatic progression. Acute toxicities were predominantly Grade 1, with one case of Grade 3 pelvic pain and no Grade 4 events.</p><p><strong>Conclusions: </strong>MRg-SBRT boost was feasible and well tolerated, achieving reasonable dose escalation with acceptable toxicity, representing a potential alternative for patients' ineligible for brachytherapy.</p><p><strong>Trial registration: </strong>MARGARITA Protocol, NCT05937958.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148956161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appearance of Stabilised Hyaluronic Acid Gel on Routine Surveillance Breast Imaging When Used to Mark the Post-Lumpectomy Tumour Bed in Breast Cancer.","authors":"Janice Yeh, Michael Chao, Mark Tacey, Jenny Sim, Sweet Ping Ng, Farshad Foroudi, Eddie Lau","doi":"10.1111/1754-9485.70149","DOIUrl":"https://doi.org/10.1111/1754-9485.70149","url":null,"abstract":"<p><strong>Introduction: </strong>Stabilised hyaluronic acid (sHA) gel can be used as a breast cancer tumour bed marker. This study aimed to assess the gel on post-treatment surveillance mammography (MMG) and breast ultrasound (USS).</p><p><strong>Methods: </strong>Patients who underwent breast-conserving surgery and adjuvant radiotherapy, with sHA gel markers (0.3-0.5 mL drops) in breast tissue had their routine 1- and 2-year post-treatment MMG and USS undergo central review by one experienced radiologist. The central review questionnaire included whether the gel was visible, description if visible, and whether it impacted diagnostic assessment of the images using a 5-point Likert scale. The images were also standardly reported by radiologists who were blinded to the gel history.</p><p><strong>Results: </strong>Of the 33 patients eligible for evaluation, sHA gel was visible on the 1-year post-treatment MMG in 3% of patients, described as well circumscribed nodules adjacent to the surgical scar. sHA gel was visible on the 1-year post-treatment USS in 38% of patients, described as simple round cystic lesions near the surgical bed. sHA gel was still visible on the same patient's 2-year post-treatment MMG (3%) and was visible on the 2-year post-treatment USS in 19% of patients. In all cases, the gel was rated 'unlikely' or 'very unlikely' to impair diagnostic assessment of the images and did not lead to any additional investigations. The blinded radiologists reported the gel as non-suspicious appearing cysts without clinical concern.</p><p><strong>Conclusion: </strong>sHA gel used as breast tumour bed marker was not visible in most patients' post-treatment MMG and USS and did not affect diagnostic assessment.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole-Body CT Utilisation in Adult Trauma: Guideline Compliance, Incidental Findings, and the Role of Anticoagulation in Low-Energy Falls at a Regional New Zealand Centre.","authors":"Vamsi Thammandra, Jonny Russell","doi":"10.1111/1754-9485.70177","DOIUrl":"https://doi.org/10.1111/1754-9485.70177","url":null,"abstract":"<p><strong>Introduction: </strong>Whole-body CT (WBCT) is central to major trauma assessment, but indiscriminate use carries a substantial radiation burden. The Central Region Trauma Network's Early Radiological Imaging in Major Trauma Guideline (CPG154), adopted at this centre, specifies criteria for WBCT and excludes low-energy falls from standing height. This pilot audit evaluated WBCT practice against CPG154 at a regional New Zealand emergency department.</p><p><strong>Methods: </strong>All adult trauma WBCT scans performed between 2 September and 31 October 2025 were reviewed retrospectively against three predefined standards: Criteria compliance (S1, target ≥ 90%); chest radiograph (CXR) before WBCT (S2, ≥ 95%); and documented follow-up of incidental findings (S3, 100%).</p><p><strong>Results: </strong>Of 73 scans identified, 70 were included. S1 compliance was 47.1% (33/70; 95% CI 35.9%-58.7%). Twenty-two scans (31.4%) were standing-height falls, which CPG154 excludes; among the remaining 48 cases, compliance was 68.8% (33/48). S2 compliance was 15.7% (11/70). Incidental findings occurred in 32.9% (23/70), all with documented follow-up (S3 100%). Acute traumatic injury was identified in 57.6% (19/33) of criteria-compliant scans and 27.3% (6/22) of standing-height fall scans. All six standing-height fall injuries occurred in patients taking anticoagulant or antiplatelet agents; none occurred in the seven patients taking neither (0/7).</p><p><strong>Conclusions: </strong>Criteria compliance was below target, principally because the standing-height exclusion was not applied at the point of request. The concentration of injuries among antithrombotic-treated fallers is hypothesis-generating and supports prospective evaluation of antithrombotic status as a possible clinical modifier.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appropriate Imaging Education as a Sustainability Intervention.","authors":"Tristen Lee","doi":"10.1111/1754-9485.70178","DOIUrl":"https://doi.org/10.1111/1754-9485.70178","url":null,"abstract":"","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148892015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing Complexities in Reirradiation Through a Standardised Pathway.","authors":"Thompson Ly, Jarryd Buckley, Jacqueline Foo, Jenny Trovato, Avis Au, Roland Yeghiaian-Alvandi, Lakmalie Perera, Ken Tiver, Kirsten van Gysen, Krishna Amulya Koti, Boon Yang Jerome Leow, Maria Azzi","doi":"10.1111/1754-9485.70173","DOIUrl":"https://doi.org/10.1111/1754-9485.70173","url":null,"abstract":"<p><p>Improvements in cancer survival have led to more patients requiring radiotherapy within or near previously irradiated regions. Despite advances in diagnostic imaging, image guidance and highly conformal delivery techniques, reirradiation remains complex because of uncertainties in radiobiology, tissue recovery, dose summation and cumulative organ-at-risk tolerance. We implemented a multidisciplinary workflow to support safe and reproducible reirradiation practice in an Australian radiation oncology department. The pathway defines the roles of radiation oncologists, radiation therapists and radiation oncology medical physicists and integrates biological dose conversion, dose summation strategy selection, tissue recovery assumptions, independent verification and documentation of uncertainty. This article describes the rationale, operational steps and early experience in our department, providing a practical framework for clinical implementation and future audit.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148887731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic Ablative Body Radiation Therapy for Spinal Oligometastases: Experience at a Single New Zealand Institution.","authors":"Kathryn Tucker, Komeela Naidoo, Nur Azri Bin Mohd Yasin, John Chin, Charles De Groot, Roger Huang","doi":"10.1111/1754-9485.70174","DOIUrl":"https://doi.org/10.1111/1754-9485.70174","url":null,"abstract":"<p><strong>Purpose: </strong>Spinal metastases are a common complication of advanced malignancy and can result in significant pain, neurological dysfunction, and reduced quality of life. In patients with oligometastatic disease, stereotactic ablative body radiation therapy (SABR) offers the potential for durable local control. This study reports outcomes following spinal SABR at Waikato Hospital and compares these with published literature.</p><p><strong>Methods: </strong>A retrospective single-centre cohort study was conducted of patients with oligometastatic spinal metastases treated with SABR at Waikato Hospital between September 2019 and December 2023. Patient, tumour, and treatment characteristics were collected from electronic records. The primary outcome was freedom from local failure. Overall survival and adverse events were also assessed.</p><p><strong>Results: </strong>Twenty-seven patients received 30 courses of spinal SABR. Median age was 66 years (range 37-81), 74.1% were male, and prostate cancer was the most common primary malignancy (48.1%). Metachronous oligorecurrent disease was present in 53.3% of patients. Patients received either 24 Gy in 2 fractions (60.0%) or 35 Gy in 5 fractions (40.0%). Median follow-up was 29.7 months. No failures occurred within 12 months. Freedom from local progression was 95.2% (95% CI 86.6-100) at 18 months and 77.6% (95% CI 57.3-100) at 3 years. Overall survival was 88.9% (95% CI 77.8-100) at 1 year and 66.3% (95% CI 49.5-88.9) at 3 years. Vertebral compression fractures occurred in 13.8% of treated sites.</p><p><strong>Conclusion: </strong>This study provides important outcome data from a New Zealand tertiary centre and demonstrates the feasibility of spinal SABR, with outcomes which are broadly consistent with those reported internationally.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148865281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}